Axovant Sciences Ltd (NASDAQ:AXON) shares hit a new 52-week low on Friday . The stock traded as low as $0.93 and last traded at $1.06, with a volume of 70095 shares. The stock had previously closed at $1.13.
AXON has been the topic of several recent analyst reports. ValuEngine upgraded shares of Axovant Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Zacks Investment Research lowered shares of Axovant Sciences from a “buy” rating to a “hold” rating in a research report on Tuesday, November 13th. Oppenheimer reiterated a “hold” rating on shares of Axovant Sciences in a research report on Sunday, November 11th. BidaskClub upgraded shares of Axovant Sciences from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 1st. Finally, Cowen reiterated a “hold” rating on shares of Axovant Sciences in a research report on Thursday, September 20th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company’s stock. Axovant Sciences presently has an average rating of “Hold” and a consensus target price of $4.56.
The company has a debt-to-equity ratio of 1.68, a current ratio of 1.97 and a quick ratio of 1.97.
Axovant Sciences Company Profile (NASDAQ:AXON)
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.
Read More: Asset Allocation, Balancing Your Investments
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.